KR20120137407A - 유전자 시그너쳐 및 전기 전도 고주파 전류의 피부에의 투입과 관련된 유전자 칩과 그에 관련된 방법 및 처리 - Google Patents
유전자 시그너쳐 및 전기 전도 고주파 전류의 피부에의 투입과 관련된 유전자 칩과 그에 관련된 방법 및 처리 Download PDFInfo
- Publication number
- KR20120137407A KR20120137407A KR1020127026405A KR20127026405A KR20120137407A KR 20120137407 A KR20120137407 A KR 20120137407A KR 1020127026405 A KR1020127026405 A KR 1020127026405A KR 20127026405 A KR20127026405 A KR 20127026405A KR 20120137407 A KR20120137407 A KR 20120137407A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- gene
- treatment
- genes
- frequency current
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 120
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 110
- 238000000034 method Methods 0.000 title claims abstract description 79
- 230000002068 genetic effect Effects 0.000 title claims description 15
- 230000000694 effects Effects 0.000 claims abstract description 67
- 108010035532 Collagen Proteins 0.000 claims abstract description 50
- 102000008186 Collagen Human genes 0.000 claims abstract description 50
- 229920001436 collagen Polymers 0.000 claims abstract description 50
- 230000014509 gene expression Effects 0.000 claims abstract description 48
- 230000002500 effect on skin Effects 0.000 claims abstract description 38
- 238000007634 remodeling Methods 0.000 claims abstract description 23
- 230000004044 response Effects 0.000 claims abstract description 22
- 238000012545 processing Methods 0.000 claims abstract description 20
- 102000004127 Cytokines Human genes 0.000 claims abstract description 14
- 108090000695 Cytokines Proteins 0.000 claims abstract description 14
- 230000003827 upregulation Effects 0.000 claims abstract description 14
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 12
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 12
- 230000001105 regulatory effect Effects 0.000 claims abstract description 4
- 230000001815 facial effect Effects 0.000 claims description 30
- 239000000523 sample Substances 0.000 claims description 29
- 238000011269 treatment regimen Methods 0.000 claims description 22
- 238000002560 therapeutic procedure Methods 0.000 claims description 18
- 238000001574 biopsy Methods 0.000 claims description 17
- 239000002537 cosmetic Substances 0.000 claims description 16
- 108020004999 messenger RNA Proteins 0.000 claims description 15
- 238000010438 heat treatment Methods 0.000 claims description 14
- 230000004547 gene signature Effects 0.000 claims description 11
- 238000012216 screening Methods 0.000 claims description 8
- 238000002493 microarray Methods 0.000 claims description 7
- 230000006698 induction Effects 0.000 claims description 4
- 230000002093 peripheral effect Effects 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 2
- 239000002853 nucleic acid probe Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 203
- 241000282414 Homo sapiens Species 0.000 description 47
- 239000002299 complementary DNA Substances 0.000 description 46
- 108020004414 DNA Proteins 0.000 description 44
- 210000001519 tissue Anatomy 0.000 description 40
- 239000000203 mixture Substances 0.000 description 35
- 230000006378 damage Effects 0.000 description 27
- 230000008859 change Effects 0.000 description 24
- 206010040954 Skin wrinkling Diseases 0.000 description 22
- 230000037303 wrinkles Effects 0.000 description 21
- 230000007246 mechanism Effects 0.000 description 14
- 238000012546 transfer Methods 0.000 description 13
- 210000004207 dermis Anatomy 0.000 description 12
- 108010014258 Elastin Proteins 0.000 description 10
- 230000032683 aging Effects 0.000 description 10
- 210000002615 epidermis Anatomy 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 239000011159 matrix material Substances 0.000 description 10
- 102000016942 Elastin Human genes 0.000 description 9
- 102100037362 Fibronectin Human genes 0.000 description 9
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 229920002549 elastin Polymers 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 8
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 102100033167 Elastin Human genes 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 230000008602 contraction Effects 0.000 description 7
- 210000004209 hair Anatomy 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- -1 MMP3 Proteins 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 5
- 208000012641 Pigmentation disease Diseases 0.000 description 5
- 102100030416 Stromelysin-1 Human genes 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 230000019612 pigmentation Effects 0.000 description 5
- 230000003716 rejuvenation Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 210000000434 stratum corneum Anatomy 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 102100037332 Aquaporin-3 Human genes 0.000 description 4
- 102000004162 Claudin-1 Human genes 0.000 description 4
- 108090000600 Claudin-1 Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102100031812 Fibulin-1 Human genes 0.000 description 4
- 102100028314 Filaggrin Human genes 0.000 description 4
- 101710088660 Filaggrin Proteins 0.000 description 4
- 101000806690 Homo sapiens Aquaporin-3 Proteins 0.000 description 4
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 4
- 101001043321 Homo sapiens Lysyl oxidase homolog 1 Proteins 0.000 description 4
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 4
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 4
- 101000645296 Homo sapiens Metalloproteinase inhibitor 2 Proteins 0.000 description 4
- 101000626163 Homo sapiens Tenascin-X Proteins 0.000 description 4
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 4
- 102100022854 Keratin, type II cytoskeletal 2 epidermal Human genes 0.000 description 4
- 102100025656 Keratin, type II cytoskeletal 6A Human genes 0.000 description 4
- 108010066321 Keratin-14 Proteins 0.000 description 4
- 108010070520 Keratin-2 Proteins 0.000 description 4
- 108010070557 Keratin-6 Proteins 0.000 description 4
- 102100031784 Loricrin Human genes 0.000 description 4
- 102100021958 Lysyl oxidase homolog 1 Human genes 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 4
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 4
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 4
- 108010050808 Procollagen Proteins 0.000 description 4
- 102100024549 Tenascin-X Human genes 0.000 description 4
- 238000002679 ablation Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000003810 hyperpigmentation Effects 0.000 description 4
- 208000000069 hyperpigmentation Diseases 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 102000007236 involucrin Human genes 0.000 description 4
- 108010033564 involucrin Proteins 0.000 description 4
- 108010079309 loricrin Proteins 0.000 description 4
- 238000011418 maintenance treatment Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000003739 neck Anatomy 0.000 description 4
- 238000013021 overheating Methods 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102100031509 Fibrillin-1 Human genes 0.000 description 3
- 101710170731 Fibulin-1 Proteins 0.000 description 3
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 3
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 3
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 description 3
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 3
- 102100039065 Interleukin-1 beta Human genes 0.000 description 3
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 3
- 108010065038 Keratin-10 Proteins 0.000 description 3
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 description 3
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000002845 discoloration Methods 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000197 pyrolysis Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000007306 turnover Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102100031611 Collagen alpha-1(III) chain Human genes 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000993285 Homo sapiens Collagen alpha-1(III) chain Proteins 0.000 description 2
- 101000846893 Homo sapiens Fibrillin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 229920001410 Microfiber Polymers 0.000 description 2
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 2
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 2
- 108010077465 Tropocollagen Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000005670 electromagnetic radiation Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004919 hair shaft Anatomy 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003658 microfiber Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000282 nail Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008458 response to injury Effects 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000036548 skin texture Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- UONOETXJSWQNOL-UHFFFAOYSA-N tungsten carbide Chemical compound [W+]#[C-] UONOETXJSWQNOL-UHFFFAOYSA-N 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- LYOKOJQBUZRTMX-UHFFFAOYSA-N 1,3-bis[[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]oxy]-2,2-bis[[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]oxymethyl]propane Chemical compound FC(F)(F)C(C(F)(F)F)(C(F)(F)F)OCC(COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F)(COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F)COC(C(F)(F)F)(C(F)(F)F)C(F)(F)F LYOKOJQBUZRTMX-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 208000020564 Eye injury Diseases 0.000 description 1
- 206010015967 Eye swelling Diseases 0.000 description 1
- 108010030229 Fibrillin-1 Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001065276 Homo sapiens Fibulin-1 Proteins 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- SFRPDSKECHTFQA-ONOWFSFQSA-N [(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] propanoate Chemical compound CCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SFRPDSKECHTFQA-ONOWFSFQSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000012874 anionic emulsifier Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000036569 collagen breakdown Effects 0.000 description 1
- 230000037369 collagen remodeling Effects 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000006529 extracellular process Effects 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 108010067415 progelatinase Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000007388 punch biopsy Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000004609 retinol derivatives Chemical class 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000037370 skin discoloration Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004441 surface measurement Methods 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 229940025573 xylocaine with epinephrine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
<도 1>
도 1은 인간 피부에 있어서 자연 발생 손상 및 복구 사이클의 개략도이며;
<도 2a 및 도 2b>
도 2a 및 도 2b는 인간 콜라겐의 특성을 도시하고;
<도 3>
도 3은 RF 전류 투입 효능의 생물학적 모델의 개략도이며;
<도 4a 및 도 4b>
도 4a 및 도 4b는 컴필레이션(compilation) 유전자의 24시간 평균 변화 배수이고;
<도 5a 및 도 5b>
도 5a 및 도 5b는 예시적인 유전자의 24시간 평균 변화 배수이며;
<도 6a 및 도 6b>
도 6a 및 도 6b는 컴필레이션 유전자의 1개월 평균 변화 배수이고;
<도 7a 및 도 7b>
도 7a 및 도 7b는 예시적인 유전자의 1개월 평균 변화 배수이며;
<도 8a 및 도 8b>
도 8a 및 도 8b는 RF 단순 열전달에 대한 2개의 그래프이고;
<도 9>
도 9는 RF 단순 열전달의 개략도이며;
<도 10>
도 10은 소비자의 눈 주위의 눈가 주름(Crow's Feet) 영역의 개략도이고;
<도 11>
도 11은 소비자 피부의 구역 A이며;
<도 12>
도 12는 소비자 피부의 구역 B이고;
<도 13>
도 13은 소비자 피부의 구역 C이며;
<도 14>
도 14는 소비자 피부의 구역 D이고;
<도 15>
도 15는 소비자 피부의 구역 E이며;
<도 16>
도 16은 소비자 피부의 구역 F이다.
Claims (11)
- 적어도 하나의 유전자가 표 1 또는 표 2로부터 선택되며 적어도 하나의 유전자가 표 3으로부터 선택되는, 포유류 피부의 조직 볼륨을 처리 온도로 가열하기에 충분하게 상기 조직 볼륨 내에서 고주파 전류를 발생시키는 것에 응답하여 포유류 피부에서 조절되는 유전자를 포함하는 유전자 패널(gene panel).
- 제1항에 있어서, 적어도 하나의 유전자는 표 1로부터 선택되며, 적어도 하나의 유전자는 표 2로부터 선택되고, 적어도 하나의 유전자는 표 3으로부터 선택되는 유전자 패널.
- 제1항 또는 제2항의 유전자 패널을 구성하는 유전자에 혼성화하여 그를 검출할 수 있는 고정화된 핵산 프로브의 세트를 포함하는 마이크로어레이(microarray).
- 에너지 전달 기구의 적용에 의해 피부를 처리하는 단계; mRNA를 처리된 피부의 샘플로부터 추출하는 단계; 및 제1항 또는 제2항의 유전자 패널의 발현 프로파일을 생성하는 단계를 포함하는, 피부를 가열함으로써 피부에 효과를 제공하도록 설계된 에너지 전달 기구의 처리 효능을 평가하는 방법.
- 얼굴 피부를 처리 요법에 따라 처리하는 단계; mRNA를 처리된 얼굴 피부의 샘플로부터 추출하는 단계; 제1항 또는 제2항의 유전자 패널의 유전자 발현 프로파일을 생성하는 단계; 유전자 발현 프로파일을 기준 프로파일과 비교하는 단계; 및 발현 프로파일이 표 1 및/또는 표 2로부터 선택되는 유전자들의 상향조절 및 표 3으로부터 선택되는 유전자들의 조절의 상당한 결여를 반영하는 경우 얼굴 처리 요법이 유효하다고 결정하는 단계를 포함하는, 피부 손상성 염증성 사이토카인 응답을 자극하지 않고서 포유류 피부에 콜라겐 및/또는 진피 리모델링 효과를 제공함에 있어서의 효능에 대하여 얼굴 피부 처리 요법을 스크리닝하는 방법.
- 제5항에 있어서, 얼굴 피부 처리 요법은 고주파 전류 발생 기구를 이용하여 처리 사이클에 걸쳐 얼굴 피부의 제1 조직 볼륨을 관통하여 펄스화된 고주파 전류를 발생시키는 것을 포함하는 방법.
- 제6항에 있어서, 처리 요법은 고주파 전류 발생 기구를 이동시키는 것과, 처리 사이클 동안 얼굴 피부의 제2 조직 볼륨을 관통하여 펄스화된 고주파 전류를 발생시키는 것을 추가로 포함하는 방법.
- 제7항에 있어서, 얼굴 피부는 귀주위 피부를 포함하며, 샘플은 처리된 귀주위 피부의 생검에 의해 얻고, 기준물은 전처리되거나 또는 비처리된 귀주위 피부의 생검에 의해 얻는 방법.
- 제8항에 있어서, 전처리되거나 또는 비처리된 귀주위 기준 피부는 처리된 귀주위 피부에 실질적으로 인접한 피부를 포함하는 방법.
- 제9항에 있어서, 표 1로부터 선택되는 유전자는 기준물에 비하여 통계적으로 1보다 큰 발현 증가 배수를 보여주는 방법.
- 미용적 피부상 효과는 피부 손상성 염증성 사이토카인 응답의 부재 하에서의 포유류 피부의 진피층에서의 콜라겐 형성 및/또는 진피 리모델링의 유도를 포함하며, 유전자 시그너쳐(genetic signature)는 표 1, 표 2 및 표 3의 각각으로부터 선택되는 적어도 하나의 유전자를 포함하는, 미용적 피부상 효과를 확인하는 데 적합한 차등 발현 유전자의 유전자 시그너쳐.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32563310P | 2010-04-19 | 2010-04-19 | |
US61/325,633 | 2010-04-19 | ||
PCT/US2011/033033 WO2011133538A1 (en) | 2010-04-19 | 2011-04-19 | Genetic signatures and gene chips associated with administration of electrically conducted radio frequency current to skin and methods and treatments relating thereto |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20120137407A true KR20120137407A (ko) | 2012-12-20 |
Family
ID=44343224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020127026405A KR20120137407A (ko) | 2010-04-19 | 2011-04-19 | 유전자 시그너쳐 및 전기 전도 고주파 전류의 피부에의 투입과 관련된 유전자 칩과 그에 관련된 방법 및 처리 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2561092A1 (ko) |
JP (1) | JP2013527756A (ko) |
KR (1) | KR20120137407A (ko) |
CN (1) | CN102869789B (ko) |
BR (1) | BR112012026870A2 (ko) |
CA (1) | CA2795671A1 (ko) |
MX (1) | MX2012012235A (ko) |
WO (1) | WO2011133538A1 (ko) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9671410B2 (en) | 2011-01-16 | 2017-06-06 | The Procter & Gamble Company | Biomarker-based methods for identifying and formulating compositions that improve skin quality and reduce the visible signs of aging in skin |
JP5841234B2 (ja) | 2011-03-31 | 2016-01-13 | ザ プロクター アンド ギャンブルカンパニー | フケ/脂漏性皮膚炎の治療に有効な皮膚活性剤を特定及び評価するためのシステム、モデル、及び方法 |
US20130261024A1 (en) * | 2012-03-30 | 2013-10-03 | The Procter & Gamble Company | System for Identifying Connections Between Perturbagens and Genes Associated with a Skin Hyperpigmentation Condition |
JP2015527630A (ja) | 2012-06-06 | 2015-09-17 | ザ プロクター アンド ギャンブルカンパニー | ヘア/頭皮ケア組成物向け化粧剤の同定システム及び方法 |
EP2885423B1 (en) * | 2012-08-15 | 2017-09-27 | The Procter and Gamble Company | Systems for identifying and evaluating skin-active agents effective for treating an array of skin disorders |
US10966916B2 (en) | 2014-11-10 | 2021-04-06 | The Procter And Gamble Company | Personal care compositions |
WO2016077325A1 (en) | 2014-11-10 | 2016-05-19 | The Procter & Gamble Company | Personal care compositions with two benefit phases |
US20160128927A1 (en) | 2014-11-10 | 2016-05-12 | The Procter & Gamble Company | Personal Care Compositions With Two Benefit Phases |
WO2019079405A1 (en) | 2017-10-20 | 2019-04-25 | The Procter & Gamble Company | AEROSOL FOAMING CLEANSER FOR THE SKIN |
CN111212625B (zh) | 2017-10-20 | 2023-05-23 | 宝洁公司 | 气溶胶泡沫洁肤剂 |
WO2020112486A1 (en) | 2018-11-29 | 2020-06-04 | The Procter & Gamble Company | Methods for screening personal care products |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3755560A (en) | 1971-06-30 | 1973-08-28 | Dow Chemical Co | Nongreasy cosmetic lotions |
US4421769A (en) | 1981-09-29 | 1983-12-20 | The Procter & Gamble Company | Skin conditioning composition |
US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
US5366443A (en) | 1992-01-07 | 1994-11-22 | Thapliyal And Eggers Partners | Method and apparatus for advancing catheters through occluded body lumens |
ATE173767T1 (de) | 1992-04-03 | 1998-12-15 | Perkin Elmer Corp | Proben zusammensetzung und verfahren |
US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
GB9401833D0 (en) | 1994-02-01 | 1994-03-30 | Isis Innovation | Method for discovering ligands |
US5458596A (en) | 1994-05-06 | 1995-10-17 | Dorsal Orthopedic Corporation | Method and apparatus for controlled contraction of soft tissue |
WO1997027317A1 (en) | 1996-01-23 | 1997-07-31 | Affymetrix, Inc. | Nucleic acid analysis techniques |
GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
US5660836A (en) | 1995-05-05 | 1997-08-26 | Knowlton; Edward W. | Method and apparatus for controlled contraction of collagen tissue |
US6241753B1 (en) | 1995-05-05 | 2001-06-05 | Thermage, Inc. | Method for scar collagen formation and contraction |
US5755753A (en) | 1995-05-05 | 1998-05-26 | Thermage, Inc. | Method for controlled contraction of collagen tissue |
US6470216B1 (en) | 1995-05-05 | 2002-10-22 | Thermage, Inc. | Method for smoothing contour irregularities of skin surface |
US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
US6228078B1 (en) | 1995-11-22 | 2001-05-08 | Arthrocare Corporation | Methods for electrosurgical dermatological treatment |
US6350276B1 (en) | 1996-01-05 | 2002-02-26 | Thermage, Inc. | Tissue remodeling apparatus containing cooling fluid |
EP1158919B1 (en) | 1999-03-09 | 2005-06-29 | Thermage, Inc. | Apparatus for treatment of tissue |
US20020087155A1 (en) * | 1999-08-30 | 2002-07-04 | Underwood Ronald A. | Systems and methods for intradermal collagen stimulation |
US6702808B1 (en) | 2000-09-28 | 2004-03-09 | Syneron Medical Ltd. | Device and method for treating skin |
EP1331892B1 (en) * | 2000-10-18 | 2006-07-05 | Mattioli Engineering Limited | Apparatus for plasma skin resurfacing |
US6889090B2 (en) | 2001-11-20 | 2005-05-03 | Syneron Medical Ltd. | System and method for skin treatment using electrical current |
US6662054B2 (en) | 2002-03-26 | 2003-12-09 | Syneron Medical Ltd. | Method and system for treating skin |
AU2003275471A1 (en) | 2002-10-07 | 2004-05-04 | Palomar Medical Technologies, Inc. | Apparatus for performing photobiostimulation |
US7643883B2 (en) * | 2005-01-28 | 2010-01-05 | Syneron Medical Ltd. | Device and method for treating skin |
SI22738A (sl) * | 2008-04-11 | 2009-10-31 | Iskra Medical, D.O.O. | Naprava za radiofrekvenčno krožno globinsko terapijo |
-
2011
- 2011-04-19 KR KR1020127026405A patent/KR20120137407A/ko not_active Application Discontinuation
- 2011-04-19 CA CA2795671A patent/CA2795671A1/en not_active Abandoned
- 2011-04-19 EP EP11718568A patent/EP2561092A1/en not_active Withdrawn
- 2011-04-19 WO PCT/US2011/033033 patent/WO2011133538A1/en active Application Filing
- 2011-04-19 MX MX2012012235A patent/MX2012012235A/es not_active Application Discontinuation
- 2011-04-19 JP JP2013506231A patent/JP2013527756A/ja active Pending
- 2011-04-19 CN CN201180019773.9A patent/CN102869789B/zh not_active Expired - Fee Related
- 2011-04-19 BR BR112012026870A patent/BR112012026870A2/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2795671A1 (en) | 2011-10-27 |
CN102869789A (zh) | 2013-01-09 |
JP2013527756A (ja) | 2013-07-04 |
BR112012026870A2 (pt) | 2017-01-10 |
CN102869789B (zh) | 2015-09-30 |
WO2011133538A1 (en) | 2011-10-27 |
EP2561092A1 (en) | 2013-02-27 |
MX2012012235A (es) | 2012-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20120137407A (ko) | 유전자 시그너쳐 및 전기 전도 고주파 전류의 피부에의 투입과 관련된 유전자 칩과 그에 관련된 방법 및 처리 | |
AU2020270508B2 (en) | C/EBP alpha short activating RNA compositions and methods of use | |
AU2019201577B2 (en) | Cancer diagnostics using biomarkers | |
CN107077536B (zh) | 使用靶基因表达的数学建模评价TGF-β细胞信号传导途径的活性 | |
KR101234281B1 (ko) | 염색체 안정화에 관한 유전자를 표적으로 하는 암세포 특이적 아포토시스 유도제 | |
AU2023251441A1 (en) | RNA containing composition for treatment of tumor diseases | |
AU2024227295A1 (en) | Molecular subtyping, prognosis, and treatment of bladder cancer | |
RU2719194C2 (ru) | Оценка активности клеточных сигнальных путей с применением вероятностного моделирования экспрессии целевых генов | |
RU2721130C2 (ru) | Оценка активности путей клеточной сигнализации с помощью линейной комбинации(ий) экспрессий генов-мишеней | |
CN110382521B (zh) | 从氧化应激区分肿瘤抑制性foxo活性的方法 | |
US6262333B1 (en) | Human genes and gene expression products | |
KR20120082906A (ko) | 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법 | |
KR101421326B1 (ko) | 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트 | |
KR20190100967A (ko) | 트리플 가이드 서열을 지닌 crispr/cas9를 사용한 엑손 스키핑 변형을 위한 최적화된 전략 | |
WO1995014772A1 (fr) | Signature genique | |
KR20140140069A (ko) | 전반적 발달장애의 진단 및 치료용 조성물 및 그 진단 및 치료 방법 | |
MXPA05005653A (es) | Determinacion y seleccion terapeutica de genes de insuficiencia cardiaca. | |
CN101258249A (zh) | 检测黑素瘤的方法和试剂 | |
KR20040065524A (ko) | 백혈병을 검사 및 치료하는 방법 | |
KR102195319B1 (ko) | 상처치료제 스크리닝용 조성물 및 이를 이용한 상처 치료제 스크리닝 방법 | |
KR101490573B1 (ko) | 포유류 피부의 상태를 조절하기 위한 조합된 에너지 및 국소 조성물 적용 | |
KR20140113021A (ko) | 약물 중독 및 의존성 확인용 바이오마커 | |
KR20100037637A (ko) | Egfr 억제제 치료에 대한 예측 마커 | |
KR20070099564A (ko) | 급성 골수성 백혈병 환자를 평가하는 방법 | |
KR102001153B1 (ko) | 유방암 예후 예측용 조성물 및 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
PA0105 | International application |
Patent event date: 20121009 Patent event code: PA01051R01D Comment text: International Patent Application |
|
PA0201 | Request for examination | ||
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20131219 Patent event code: PE09021S01D |
|
N231 | Notification of change of applicant | ||
PN2301 | Change of applicant |
Patent event date: 20140204 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20140926 Patent event code: PE09021S01D |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20150129 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20140926 Comment text: Notification of reason for refusal Patent event code: PE06011S01I Patent event date: 20131219 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |